A Study to Evaluate OPTI-BIOME™ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population
NCT ID: NCT02950012
Last Updated: 2021-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2016-10-31
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OPTI-BIOME™ Bacillus subtilis MB40
OPTI-BIOME™ Bacillus subtilis MB40
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OPTI-BIOME™ Bacillus subtilis MB40
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI 18.5-29.9 ±1 kg/m2
3. Abdominal bloating intensity score ≥5 and at least two days of bloating over the 2 weeks prior to screening (assessed at screening by Abdominal Bloating questionnaire)
4. Participants categorized as 'high bloaters' as defined by an average bloating score ≥ 5 during the run-in period assessed at baseline by question 3 of the Modified Daily Abdominal Discomfort, Gas, and Bloating Questionnaire, AND/OR, participants categorized as 'high frequency bloaters' as defined by greater than 7 days of high bloating (defined above) during the run-in period.
* For females, this should not include abdominal discomfort or bloating experienced during menstruation, if such symptoms occur due to menstrual cycle females should go through another run-in period.
5. If female, participant is not of child bearing potential, which is defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with \> 1 year since last menstruation) OR
Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
* Hormonal contraceptives (stable for 1 month) including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
* Double-barrier method
* Intrauterine devices
* Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
* Vasectomy of partner (shown successful as per appropriate follow-up)
6. Healthy as determined by laboratory results, medical history, and physical exam
7. Agrees to abstain from consuming unpasteurized bacteria-fermented foods including cheese and yogurt for 1 week prior to screening visit and throughout the study
8. Agrees to abstain from using fiber supplements 2 weeks prior to screening and for the duration of the study
9. Agrees to maintain current dietary habits and activity/training levels for two weeks prior to baseline and for the course of the study
10. Agrees to avoid probiotics for one week prior to screening and for the course of the study
11. Willingness to complete all the study requirements and attend all clinic visits.
12. Has given voluntary, written, informed consent to participate in the study
Exclusion Criteria
2. History of chronic inflammation or structural abnormality of the digestive tract (inflammatory bowel disease, duodenal or gastric ulcer, intestinal obstruction, or symptomatic cholelithiasis)
3. Nocturnal and/or progressive abdominal pain (abdominal pain that increases in intensity and is consistent on regular basis)
4. Significant weight loss over the past 3 months (significance to be determined by the Qualified Investigator)
5. Type 1 and type 2 diabetes
6. History of colorectal cancer, anal abscess, anal fistula, anal fissure, anal stenosis, gastric retention or obstruction, bowel resection, rectocele, or colostomy
7. Cancer except skin cancers completed excised with no chemotherapy or radiation following and with a negative follow up.
8. Diagnosis of adenomatous polyposis, irritable bowel syndrome, chronic gastritis or functional dyspepsia, crohn disease, and celiac disease Renal or hepatic insufficiency
9. Gastrointestinal bleeding or acute infection
10. Immunodeficiency
11. History of organ transplant
12. Use of antibiotics within 4 weeks of randomization Routine (at least 3 times per week) consumption of probiotic or prebiotic supplements or supplemented foods and are unwilling to stop at least one week prior to screening and throughout the study
13. Use of immunosuppressant drugs
14. Change in anti-psychotic medication within 3 months of randomization
15. Abdominal surgery within 6 months of randomization
16. Plan to donate blood during the study or within 30 days of completing the study
17. Participation in a clinical research trial within 30 days prior to randomization
18. Allergy or sensitivity to study supplement or placebo ingredients
19. Alcohol abuse (\>2 standard alcoholic drinks per day) or drug abuse within the last 6 months
20. Use of Medicinal Marijuana
21. Cognitively impaired and/or unable to give informed consent
22. Unstable medical conditions
23. Clinically significant abnormal laboratory results at screening
24. Any other condition which in the Qualified Investigator's opinion may adversely affect the volunteer's ability to complete the study or its measures or which may pose significant risk to the volunteer
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KGK Science Inc.
INDUSTRY
BIO-CAT Microbials, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tetyana Pelipyagina, MD'
Role: PRINCIPAL_INVESTIGATOR
KGK Science Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KGK Clinical Trials Center
Foothill Ranch, California, United States
KGK Clinical Trials Center
Orlando, Florida, United States
KGK Synergize Inc.
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Penet C, Kramer R, Little R, Spears JL, Parker J, Iyer JK, Guthrie N, Evans M. A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating. Altern Ther Health Med. 2021 Jun;27(S1):146-157.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16OBHB
Identifier Type: -
Identifier Source: org_study_id